ClinicalTrials.gg

Program

rezatapopt

Also written as “PC14586” and “[14C]-PC14586”.

Its studies are mostly in Neoplasm Metastasis, led by PMV Pharmaceuticals.

Furthest: phase 2, since Oct 1, 20205 company-led studies, 2 open or runningNext primary completion: Dec 15, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PMV Pharmaceuticals52 open or runningphase 2since Oct 1, 2020Oct 1, 2020Dec 15, 2026phase 2 · NCT04585750

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2020First study: phase 2 study in Neoplasm MetastasisFirst studyNCT04585750 · 300 planned · United States, Australia, France and more
  2. Jan 7, 2022Phase 1 study in Healthy VolunteersNCT05249348 · 34 enrolled · United States
  3. Aug 22, 2022Phase 1 study in Healthy Male VolunteersNCT05523687 · 8 enrolled · United States
  4. Mar 25, 2024Phase 1 study in Healthy VolunteersNCT06362642 · 12 enrolled · United States
  5. Jan 5, 2026Phase 1 study in TP53 Y220C MutationNCT07372625 · 14 planned · United States

Ahead

  1. Dec 15, 2026Primary completion: phase 2 study in Neoplasm MetastasisNCT04585750
  2. Mar 2027Primary completion: phase 1 study in TP53 Y220C MutationNCT07372625

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07372625TP53 Y220C Mutation · United States1RecruitingMar 202714
NCT06362642Healthy Volunteers · United States1CompletedOct 22, 202412
NCT05523687Healthy Male Volunteers · United States1CompletedNov 30, 20228
NCT05249348Healthy Volunteers · United States1CompletedJun 9, 202234
NCT04585750Neoplasm Metastasis · United States, Australia, France and more2RecruitingDec 15, 2026300

How it is read

Names in the registry

  • “rezatapopt”, 2 entries
  • “PC14586”, 2 entries
  • “[14C]-PC14586”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.